Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin in combination with VRd in newly diagnosed multiple myeloma
NCT04091126Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2019
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 1, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (10 cohorts), sponsored by GSK. Primary endpoints: Dose-Limiting Toxicities at 9 weeks and Adverse Events and Serious Adverse Events at 54 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04091126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091126.